IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer

Background: Biliary tract cancers (BTCs) are heterogenous, highly aggressive tumors that harbor a dismal prognosis for which more effective treatments are needed. The role of cancer immunotherapy in BTC remains to be characterized. The tumor microenvironment (TME) of BTC is highly immunosuppressed a...

Full description

Bibliographic Details
Main Authors:	Stephen P. Hack, Wendy Verret, Sohail Mulla, Bo Liu, Yulei Wang, Teresa Macarulla, Zhenggang Ren, Anthony B. El-Khoueiry, Andrew X. Zhu
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-07-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359211036544

Similar Items

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
by: Riad Salem, et al.
Published: (2021-08-01)

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
by: Shukui Qin, et al.
Published: (2021-04-01)

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
by: Breder, V., et al.
Published: (2022)

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
by: Jordi Remon, MD, et al.
Published: (2021-01-01)

Chemotherapy for Biliary Tract Cancer
by: Sang Myung Woo
Published: (2017-03-01)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
by: Ali AL Zahrani, et al.
Published: (2021-03-01)

Chemotherapy for Biliary Tract Cancer in 2021
by: Takashi Sasaki, et al.
Published: (2021-07-01)

A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study
by: Sung-Nan Pei, et al.
Published: (2021-07-01)

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
by: Arndt Vogel, et al.
Published: (2021-05-01)

Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
by: Yulei Wang, et al.
Published: (2021-08-01)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
by: Chiun Hsu, et al.
Published: (2021-07-01)

Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
by: I. А. Dzhanyan, et al.
Published: (2021-06-01)

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
by: Masatoshi Kudo
Published: (2021-02-01)

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
by: Jeffrey J. Wallin, et al.
Published: (2016-08-01)

A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
by: Masatoshi Kudo
Published: (2020-03-01)

Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab”
Published: (2021-09-01)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
by: Hideki Iwamoto, et al.
Published: (2021-06-01)

Adjuvant Radio-chemotherapy for extrahepatic biliary tract cancers
by: Mentha Gilles, et al.
Published: (2011-06-01)

Prolonged response to atezolizumab with bevacizumab plus chemotherapy in a patient with lung cancer harboring mutation in EGFR after Afatinib treatment: A case report
by: Hayato Koba, et al.
Published: (2021-12-01)

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Chi-Leung Chiang, et al.
Published: (2021-02-01)

Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature
by: Balraj Singh MD, et al.
Published: (2021-03-01)

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
by: Yi Yu MD, et al.
Published: (2021-05-01)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
by: Yuwa Ando, et al.
Published: (2021-08-01)

Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting
by: Maria Corina Plaz Torres, et al.
Published: (2021-07-01)

Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition
by: Lei Zhang, et al.
Published: (2019-04-01)

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
by: Colby S. Shemesh, et al.
Published: (2021-06-01)

Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion
by: Kulik L, et al.
Published: (2020-12-01)

Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer
by: Hyera Kim, et al.
Published: (2020-01-01)

Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract
by: Zabernigg August, et al.
Published: (2012-09-01)

Clinical case of long-term use of atezolizumab and bevacizumab in the first-line treatment of recurrence of non-small cell lung cancer
by: O. A. Rozonova, et al.
Published: (2020-07-01)

A subgroup analysis from the IMvigor130 study in patients with upper tract vs. lower tract locally advanced or metastatic urothelial carcinoma treated with atezolizumab plus platinum-based chemotherapy
by: A. Bamias, et al.
Published: (2020-11-01)

Correction to: Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer
by: Hyera Kim, et al.
Published: (2020-07-01)

Pregnancy and the Biliary Tract
by: Tuvia Gilat, et al.
Published: (2000-01-01)

"Steinstrasse" in the Biliary Tract.
by: Guzmán-Calderón, Edson
Published: (2017)

Biliary Tract Review and Recent Progress
Published: (2023)

Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer
by: Bin Wu, et al.
Published: (2020-05-01)

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
by: Nikolai A. Ognerubov, et al.
Published: (2021-08-01)

Gemcitabine and S-1 Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer:A Retrospective Study
by: Kazuhito Mita, et al.
Published: (2010-12-01)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
by: Young Saing Kim, et al.
Published: (2017-01-01)

Inflammatory pseudotumor of the biliary tract
by: R Subhash, et al.
Published: (2012-01-01)